Spero Therapeutics (NASDAQ:SPRO) Stock Price Crosses Below 200-Day Moving Average - What's Next?

Key Points

• Spero Therapeutics shares fell below their 200-day moving average, trading as low as $1.17 and last changing hands at $1.19, down 5.6%. The stock’s 200-day average is $2.00, while its market capitalization is approximately $69.3 million.
• Analyst sentiment remains cautious, with one Buy rating and three Hold ratings, producing a consensus Hold rating and an average price target of $6.00. HC Wainwright raised its target to $6.00 and maintained a Buy rating.
• Institutional investors own 25.6% of the company, with BlackRock and other funds recently establishing or expanding positions. Spero reported quarterly EPS of negative $0.16, slightly better than the consensus estimate of negative $0.17.

Shares of Spero Therapeutics, Inc. (NASDAQ:SPRO - Get Free Report) passed below its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $2.00 and traded as low as $1.1705. Spero Therapeutics shares last traded at $1.19, with a volume of 906,915 shares traded.

Wall Street Analyst Weigh In

Several research firms recently issued reports on SPRO. Compass Point raised Spero Therapeutics to a "neutral" rating in a research note on Monday, September 14th. Zacks Research upgraded Spero Therapeutics to a "hold" rating in a research note on Monday, September 14th. HC Wainwright raised their price target on Spero Therapeutics from $5.00 to $6.00 and gave the company a "buy" rating in a report on Monday, September 14th. Finally, Weiss Ratings upgraded Spero Therapeutics from a "sell (d-)" rating to a "hold (c-)" rating in a research report on Wednesday, August 12th. One research analyst has rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, Spero Therapeutics presently has a consensus rating of "Hold" and an average target price of $6.00.

Spero Therapeutics Trading Down 5.6%

The stock's fifty day moving average price is $1.20 and its 200 day moving average price is $2.00. The stock has a market cap of $69.30 million, a P/E ratio of 10.82 and a beta of 1.50.

Spero Therapeutics (NASDAQ:SPRO - Get Free Report) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.01. Spero Therapeutics had a net margin of 24.90% and a return on equity of 16.17%. On average, analysts anticipate that Spero Therapeutics, Inc. will post -0.58 earnings per share for the current year.

Institutional Investors Weigh In On Spero Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Susquehanna Fundamental Investments LLC purchased a new position in shares of Spero Therapeutics in the 2nd quarter worth about $36,000. Global Retirement Partners LLC bought a new position in shares of Spero Therapeutics during the 2nd quarter valued at about $55,000. Intrepid Family Office LLC raised its holdings in shares of Spero Therapeutics by 50.0% during the 4th quarter. Intrepid Family Office LLC now owns 165,000 shares of the company's stock valued at $384,000 after buying an additional 55,000 shares in the last quarter. GSA Capital Partners LLP purchased a new position in shares of Spero Therapeutics during the 2nd quarter valued at about $632,000. Finally, BlackRock Inc. purchased a new position in shares of Spero Therapeutics during the 2nd quarter valued at about $1,314,000. Institutional investors own 25.60% of the company's stock.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company develops therapies for serious bacterial infections and certain rare diseases, with a focus on addressing conditions for which existing treatment options are limited or inadequate.

Spero's lead program is tebipenem pivoxil hydrobromide, an oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections. The company's pipeline has also included SPR720, an investigational oral therapy for nontuberculous mycobacterial pulmonary disease, and SPR206, an investigational intravenous antibiotic intended for use against serious hospital infections caused by drug-resistant bacteria.

Founded in 2013, Spero has advanced its programs through collaborations and development partnerships, including a former agreement with GlaxoSmithKline.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.